Company Overview of 3-V Biosciences, Inc.
3-V Biosciences, Inc. operates as a biopharmaceutical company that discovers and develops therapeutics for the treatment of oncology and infectious diseases. The company offers a TVB-2640, a fatty acid synthase inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. It also focuses on developing antiviral therapeutic candidates for respiratory syncytial virus, cytomegalovirus, and other human pathogens. The company was incorporated in 2006 and is based in Menlo Park, California.
1050 Hamilton Court
Menlo Park, CA 94025
Founded in 2006
Key Executives for 3-V Biosciences, Inc.
Compensation as of Fiscal Year 2014.
3-V Biosciences, Inc. Key Developments
3-V Biosciences, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM
Dec 2 14
3-V Biosciences, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Merdad V. Parsey, Chief Executive Officer, President and Director.
3-V Biosciences, Inc. Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors
Dec 4 13
3-V Biosciences, Inc. announced the recent initiation of a Phase 1 clinical study of TVB-2640 in patients with advanced solid tumors. TVB-2640 is an oral, proprietary fatty acid synthase (FASN) inhibitor being evaluated for the treatment of solid tumors. FASN is an enzyme responsible for the synthesis of palmitic acid and has a key role in tumor metabolism, lipid signaling and tumor cell survival. The Phase 1 open-label, dose-escalation trial will enroll patients with advanced solid tumors whose cancer has become refractory to standard therapy, and for whom no useful treatment exists. Patients will receive TVB-2640 once daily for 21 days. The primary endpoint for the Phase 1 study is the identification of any dose-limiting toxicities and the establishment of a maximum-tolerated dose (MTD) for oral TVB-2640. Secondary and exploratory endpoints include safety, pharmacokinetics, and initial signs of efficacy and evidence of FASN biomarker activity. FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers. In a series of preclinical studies, 3-V's FASN inhibitors demonstrated potent activity against multiple tumor types, including breast, lung, pancreatic, ovarian and colon cancers. FASN inhibition reduced cell proliferation and induced apoptosis (cell death) in a dose-dependent manner and single-agent FASN inhibition both blocked tumor growth and resulted in significant tumor regression in patient-derived xenografts. In addition, 3-V has demonstrated potential synergy of its FASN inhibitors with cytotoxic agents.
3-V Biosciences, Inc. Names William McCulloch as Chief Medical Officer
Nov 21 13
3-V Biosciences, Inc. announced that William McCulloch, MB, ChB, FRCP, FFPM has joined the company as Chief Medical Officer. Dr. McCulloch brings nearly three decades of senior research and development experience to 3-V, including an extensive preclinical and clinical development background in oncology. Dr. McCulloch will be responsible for 3-V's clinical, medical affairs and regulatory functions, overseeing strategy and implementation for the advancement of 3-V's pipeline of proprietary therapeutic candidates. Dr. McCulloch previously served as Chief Medical Officer at Gloucester Pharmaceuticals, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|